Trending Stock News

Tricon Capital Group Inc. (TCN) EPS Estimated At $0.27; Vivus (VVUS) Shorts Raised By 3.88%

Analysts expect Tricon Capital Group Inc. (TSE:TCN) to report $0.27 EPS on May, 9.They anticipate $0.09 EPS change or 50.00% from last quarter’s $0.18 EPS. T_TCN’s profit would be $36.08M giving it 9.14 P/E if the $0.27 EPS is correct. After having $0.50 EPS previously, Tricon Capital Group Inc.’s analysts see -46.00% EPS growth. The stock decreased 1.00% or $0.1 during the last trading session, reaching $9.87. About 107,420 shares traded. Tricon Capital Group Inc. (TSE:TCN) has 0.00% since April 9, 2017 and is . It has underperformed by 11.55% the S&P500.

Vivus Inc (NASDAQ:VVUS) had an increase of 3.88% in short interest. VVUS’s SI was 5.54M shares in April as released by FINRA. Its up 3.88% from 5.34 million shares previously. With 511,000 avg volume, 11 days are for Vivus Inc (NASDAQ:VVUS)’s short sellers to cover VVUS’s short positions. The SI to Vivus Inc’s float is 6.1%. The stock decreased 4.33% or $0.0163 during the last trading session, reaching $0.3598. About 272,229 shares traded. VIVUS, Inc. (NASDAQ:VVUS) has declined 65.45% since April 9, 2017 and is downtrending. It has underperformed by 77.00% the S&P500.

Among 3 analysts covering Tricon Capital Group (TSE:TCN), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Tricon Capital Group had 26 analyst reports since August 19, 2015 according to SRatingsIntel. As per Wednesday, January 27, the company rating was maintained by RBC Capital Markets. National Bank Canada maintained Tricon Capital Group Inc. (TSE:TCN) on Tuesday, August 25 with “Outperform” rating. As per Thursday, October 1, the company rating was maintained by RBC Capital Markets. The stock of Tricon Capital Group Inc. (TSE:TCN) earned “Outperform” rating by RBC Capital Markets on Thursday, February 25. The company was maintained on Monday, August 15 by Canaccord Genuity. The firm has “Outperform” rating by RBC Capital Markets given on Wednesday, June 1. RBC Capital Markets maintained the shares of TCN in report on Wednesday, June 29 with “Outperform” rating. On Wednesday, August 19 the stock rating was maintained by TD Securities with “Buy”. The rating was maintained by RBC Capital Markets on Wednesday, May 31 with “Outperform”. The stock of Tricon Capital Group Inc. (TSE:TCN) earned “Outperform” rating by RBC Capital Markets on Wednesday, February 1.

Tricon Capital Group Inc. is a principal investor and asset manager focused on the residential real estate industry in North America. The company has market cap of $1.32 billion. The firm owns and manages on behalf of third-party investors a portfolio of investments in land and homebuilding assets, single-family rental homes, manufactured housing communities, and multi-family development projects. It has a 18.28 P/E ratio. The business objective of the firm is to invest for investment income and capital appreciation through its principal investment business and to earn fee income through private funds and advisory business.

VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company has market cap of $38.15 million. The firm offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It currently has negative earnings. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension.

Investors sentiment increased to 0.57 in 2017 Q4. Its up 0.04, from 0.53 in 2017Q3. It is positive, as 9 investors sold VIVUS, Inc. shares while 21 reduced holdings. 8 funds opened positions while 9 raised stakes. 25.91 million shares or 20.65% less from 32.65 million shares in 2017Q3 were reported. Maple Mngmt Inc has 24,500 shares for 0% of their portfolio. Next Finance reported 0.01% in VIVUS, Inc. (NASDAQ:VVUS). Ajo L P has invested 0% in VIVUS, Inc. (NASDAQ:VVUS). Hanson Mcclain Incorporated has 0% invested in VIVUS, Inc. (NASDAQ:VVUS). Jpmorgan Chase Company accumulated 2,500 shares. California Pub Employees Retirement Systems reported 0% of its portfolio in VIVUS, Inc. (NASDAQ:VVUS). Citadel Advsrs Ltd Company invested in 0% or 40,735 shares. Cetera Advisor Limited Liability holds 0% or 10,000 shares in its portfolio. D E Shaw And Company Inc holds 0% or 325,769 shares. Royal Bancorp Of Canada holds 0% or 271,410 shares in its portfolio. Goldman Sachs Grp accumulated 0% or 71,428 shares. 107 were reported by Tortoise Invest Mgmt Limited Liability Corporation. Susquehanna Intl Llp holds 0% or 114,123 shares in its portfolio. Caprock Group Inc reported 28,000 shares. Financial Architects Incorporated owns 4,000 shares.

Among 2 analysts covering Vivus (NASDAQ:VVUS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vivus had 3 analyst reports since July 31, 2015 according to SRatingsIntel. WallachBeth Capital upgraded VIVUS, Inc. (NASDAQ:VVUS) on Thursday, November 5 to “Buy” rating. The stock of VIVUS, Inc. (NASDAQ:VVUS) earned “Outperform” rating by RBC Capital Markets on Friday, July 31. The firm has “Hold” rating given on Wednesday, August 5 by Zacks.

VIVUS, Inc. (NASDAQ:VVUS) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *